Gerresheimer AG announced that it has opened a new development center for medical plastic systems in Dongguan City, China. The new Technical Competence Center (TCC) in China will be managing large-scale projects.
Gerresheimer AG announced that it has opened a new development center for medical plastic systems in Dongguan City, China. The new Technical Competence Center (TCC) in China will be managing large-scale projects.
“The new center in China ensures that we can optimally meet the growing demand in the Asian market,” said Andreas Schütte, member of Gerresheimer Management Board for Plastics & Devices, in a press release. Schütte added that the company plans to have development operations in addition to local production operations to enable closer collaboration with its customers in China.
The company currently has two other development centers in Wackersdorf, Germany and Peachtree City, US. Gerresheimer’s development centers produce medical plastic systems such as insulin pens, inhalers, lancets and auto-injectors for industrialization. All interdisciplinary functions up to a product’s series production stage are performed at these sites.
The local projects implemented at the development centers in collaboration with the other sites include series design, manufacturing equipment engineering, process development, project management, quality planning, tool making, automation technology, production initiation and pre-series production.
At its Dongguan City production facility, Gerresheimer has been manufacturing drug delivery devices such as inhalers and lancets for diabetes sufferers, and infusion products, since 2006.
Source: Gerresheimer
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.